Axcella Health (Axcella Health) Inventories, Inventories Adjustments : $0.00 Mil (As of Jun. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Axcella Health Inventories, Inventories Adjustments?

Axcella Health's Inventories, Inventories Adjustments for the quarter that ended in Jun. 2023 was $0.00 Mil.

Axcella Health Inventories, Inventories Adjustments Historical Data

The historical data trend for Axcella Health's Inventories, Inventories Adjustments can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axcella Health Inventories, Inventories Adjustments Chart

Axcella Health Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Inventories, Inventories Adjustments

Get a 7-Day Free Trial

Axcella Health Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Inventories, Inventories Adjustments	Get a 7-Day Free Trial															-	-	-	-	-

Axcella Health Inventories, Inventories Adjustments Calculation

Inventories, Inventories Adjustments represents certain charges made in the current period in inventory resulting from breakage, spoilage, employee theft and shoplifting, etc.

Axcella Health (Axcella Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Axcella Health Inc (OTCPK:AXLA) » Definitions » Inventories, Inventories Adjustments

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 1270, Littleton, MA, USA, 01460

Website

https://www.axcellahealth.com

Axcella Health Inc a biotechnology company focused on treating complex diseases and improve health using endogenous metabolic modulator, or EMM, compositions. Its product candidates are comprised of multiple EMMs that are engineered in distinct combinations and ratios to simultaneously impact multiple biological pathways. The company's pipeline includes lead therapeutic candidates, AXA1665 for the reduction in risk of recurrent overt hepatic encephalopathy, and AXA1125 for non-alcoholic steatohepatitis.

Executives

Paul Fehlner	officer: Senior Vice President, CIPO	C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
William Hinshaw	director, officer: President and CEO	C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
L.p. Fpa,	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Fpa General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Societe Des Produits Nestle S.a.	10 percent owner	AVENUE NESTLE 55, VEVEY V8 CH-1800
Flagship Pioneering Inc.	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Flagship Ventures Fund Iv, L.p.	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Torben Straight Nissen	director	C/O RUBIUS THERAPEUTICS, 325 VASSAR ST., STE. 1A, CAMBRIDGE MA 02139
Robert L. Rosiello	director	400 SOMERSET CORPORATE BOULEVARD, BRIDGEWATER NJ 08807
Margaret Koziel	officer: Chief Medical Officer	C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Michael Rosenblatt	director	2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Martin Hendrix	director	C/O PROMETHEUS BIOSCIENCES, INC., 9410 CARROLL PARK DRIVE, SAN DIEGO CA 92121
Paul J Sekhri	director	C/O VEEVA SYSTEMS INC., 4637 CHABOT DRIVE, SUITE 210, PLEASANTON CA 94588
David R Epstein	director	INTERNATIONAL FLAVORS & FRAGRANCES INC., 521 W. 57TH STREET, NEW YORK NY 10019
Robert Crane	officer: Chief Financial Officer	101 CONVENTION CENTER DRIVE SUITE 310, LAS VEGAS NV 89109